Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04821830 · ClinicalTrials.gov registry record · Phase 4
Vigor and the LDR in Parkinson Disease
A Phase 4 study, sponsored by University of Michigan.
- Completed
- Registry status
- Phase 4
- Development phase
- 19
- Enrollment target
NCT04821830 is a Phase 4 study that has completed, run by University of Michigan. The registered enrollment target is 19 participants.
The verdict
NCT04821830, a Phase 4 study, has completed, sponsored by University of Michigan.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 19 participants
- Enrollment target
Study Summary
Parkinson disease (PD) is a common disorder in which reduced speed of movement results from inadequate brain production of the chemical dopamine. The most effective treatment for PD is the drug levo-dopa, which partially replaces brain dopamine. Despite decades of successful use, how levo-dopa improves speed of movement in PD is not understood. This observational study recruits participants who have been prescribed levo-dopa by their treating physicians. Before their first dose, immediately after their first dose and later, when their dose has been stabilized, they will engage with the research team to participate in a few simple experiments to measure speed, grip strength, tremor, and stability (on and off of treatment). The purpose of these experiments is to understand how levo-dopa treatment in Parkinson disease enhances movement speed. An important but not understood component of levo-dopa action, the Long Duration Response (LDR), lasts for days to weeks. A basic function of dopamine signaling in the brain is modulation of motivation - the coupling between effort and action values. These experiments will determine if the LDR is associated with relative normalization of motivation function in the brain. The motivation behavior of recently diagnosed PD participants will be examined before and after treatment with levo-dopa to determine if the magnitude of the LDR is correlated with improvements in motivation behavior.
Interventions
- DRUG carbidopa/levodopa, as prescribed by treating physician
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 19 participants |
| Start Date | 2020-02-12 |
| Est. Completion | 2024-04-25 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04821830
The ClinicalTrials.gov registry entry for NCT04821830 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 19 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Michigan, which has 1,327 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which carbidopa/levodopa, as prescribed by treating physician is the first listed.
NCT04821830 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04821830 about?
NCT04821830 is a clinical study titled "Vigor and the LDR in Parkinson Disease". Parkinson disease (PD) is a common disorder in which reduced speed of movement results from inadequate brain production of the chemical dopamine. The most effective treatment for PD is the drug levo-dopa, which partially replaces brain dopamine. Despite decades of successful use, how levo-dopa impro...
What is the current status of trial NCT04821830?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 19 participants. The study started on 2020-02-12. Estimated completion is 2024-04-25.
What interventions are being tested in trial NCT04821830?
The interventions under investigation include: carbidopa/levodopa, as prescribed by treating physician (DRUG).
Who is sponsoring clinical trial NCT04821830?
This trial is sponsored by University of Michigan, which has 1,327 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.